Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
Outcomes of Treatment With Tralokinumab in Dupilumab-Experienced and Dupilumab-Naïve Patients With Atopic Dermatitis
TAKE-HOME MESSAGE
- This case series assessed the effectiveness and safety of treatment with tralokinumab for at least 6 weeks in patients with atopic dermatitis. Most patients (86%) had switched from dupilumab to tralokinumab after initial improvement of their atopic dermatitis and a lack or loss of effectiveness or adverse events. After switching to tralokinumab, the Eczema Area and Severity Index scores improved at 12 and 24 weeks. At the data cutoff, 52% of the patients continued tralokinumab use for a median of 47 weeks, and 9 patients discontinued treatment owing to ineffectiveness. Of note, 80% of the patients experiencing ocular adverse events owing to dupilumab reported resolution or reduction of these events after switching to tralokinumab.
- Tralokinumab may be a viable therapy for patients on dupilumab who begin to experience a loss of effectiveness of therapy or intolerable ocular side effects.
abstract
This abstract is available on the publisher's site.
Access this abstract nowTralokinumab and dupilumab are monoclonal antibodies that target the Th2 immune response and are approved for moderate-to-severe atopic dermatitis (AD). Dupilumab targets the interleukin (IL)-4 receptor and blocks both IL-4 and IL-13 signalling, whereas tralokinumab specifically blocks the IL-13 receptor. The real-world effectiveness and safety of tralokinumab (with or without concomitant topical corticosteroids) were evaluated in this case series of 29 patients (aged 19–80 years) treated with tralokinumab for at least 6 weeks at the Department of Dermatology and Venereology, Lausanne University Hospital, Switzerland, between 8 July 2022 and 13 March 2024. Effectiveness was assessed using the Eczema Area and Severity Index (EASI) and Physician Global Assessment (PGA) scores.
Additional Info
Disclosure statements are available on the authors' profiles:
Single-centre experience with tralokinumab in dupilumab-experienced and naïve patients with atopic dermatitis
J Eur Acad Dermatol Venereol 2024 Sep 18;[EPub Ahead of Print], C Fossati, E Guenova, C Conrad, M Gilliet, T SeremetFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This group reports their experience with tralokinumab, an IL-13 receptor inhibitor, in 29 patients with long-standing pre-treated atopic dermatitis. Of note, 25 patients had transitioned from dupilumab to tralokinumab, mostly owing to a lack or loss of effectiveness. Improved disease severity and limited side effects were reported, supporting the use of tralokinumab in this patient population.
The systemic treatment landscape for atopic dermatitis has dramatically changed for adults and children in the past decade. We now have several effective options for our patients with moderate and severe disease, including dupilumab, tralokinumab, and JAK inhibitors, and can avoid broad immunosuppression. Moreover, our current dermatology trainees will not experience the patient suffering and provider frustration of the past.